INTERCEPT PHARMACEUTICALS IN's ticker is ICPT and the CUSIP is 45845P108. A total of 152 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q1 2022. The put-call ratio across all filers is 0.68 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $1,771,441 | +120.2% | 95,547 | +31.3% | 0.00% | – |
Q2 2023 | $804,560 | -19.5% | 72,745 | -2.3% | 0.00% | – |
Q1 2023 | $999,984 | -49.3% | 74,459 | -53.3% | 0.00% | -100.0% |
Q4 2022 | $1,972,557 | -9.4% | 159,463 | +2.2% | 0.00% | 0.0% |
Q3 2022 | $2,177,000 | +0.1% | 156,087 | -0.9% | 0.00% | 0.0% |
Q2 2022 | $2,175,000 | -14.7% | 157,510 | +0.5% | 0.00% | 0.0% |
Q1 2022 | $2,550,000 | +0.9% | 156,715 | +1.0% | 0.00% | 0.0% |
Q4 2021 | $2,527,000 | +226.5% | 155,108 | +197.5% | 0.00% | – |
Q3 2021 | $774,000 | -88.3% | 52,143 | +1.1% | 0.00% | -100.0% |
Q1 2016 | $6,628,000 | -31.3% | 51,588 | -20.2% | 0.00% | -40.0% |
Q4 2015 | $9,654,000 | -10.6% | 64,644 | -0.7% | 0.01% | -16.7% |
Q3 2015 | $10,796,000 | -99.9% | 65,093 | -18.2% | 0.01% | -40.0% |
Q2 2015 | $19,209,503,000 | -22.8% | 79,582 | -9.8% | 0.01% | -23.1% |
Q1 2015 | $24,873,600,000 | +84.9% | 88,198 | +2.3% | 0.01% | +85.7% |
Q4 2014 | $13,449,072,000 | +826.8% | 86,212 | +1859.4% | 0.01% | +600.0% |
Q1 2014 | $1,451,076,000 | – | 4,400 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Samsara BioCapital, LLC | 640,688 | $9,514,000 | 1.49% |
CM Management, LLC | 45,000 | $668,000 | 0.50% |
EULAV Asset Management | 660,000 | $9,801,000 | 0.26% |
DLD Asset Management, LP | 225,200 | $3,346,000 | 0.24% |
Virtus ETF Advisers LLC | 21,387 | $318,000 | 0.14% |
GSA CAPITAL PARTNERS LLP | 79,145 | $1,175,000 | 0.12% |
Hennion & Walsh Asset Management, Inc. | 136,720 | $2,030,000 | 0.11% |
ALTRINSIC GLOBAL ADVISORS LLC | 168,800 | $2,507,000 | 0.08% |
Inspire Investing, LLC | 31,868 | $473,000 | 0.06% |
DUALITY ADVISERS, LP | 51,196 | $760,000 | 0.06% |